FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896615022> ?p ?o ?g. }

• W2896615022 endingPage "214" @default.
• W2896615022 startingPage "207" @default.
• W2896615022 abstract "Abstract Background Previous studies in human immunodeficiency virus (HIV)-positive individuals on thymidine analogue backbone antiretroviral therapy (ART) with either nevirapine or efavirenz have suggested poorer virological outcomes in the presence of pretreatment drug resistance (PDR). We assessed the impact of PDR on virological suppression (VS; <50 copies/mL) in individuals prescribed primarily tenofovir/emtricitabine/efavirenz in rural KwaZulu-Natal within a treatment-as-prevention trial. Methods Among 1557 HIV-positive individuals who reported no prior ART at study entry and provided plasma samples, 1328 individuals with entry viral load (VL) >1000 copies/mL had next-generation sequencing (NGS) of the HIV pol gene with MiSeq technology. Results were obtained for 1148 individuals, and the presence of PDR was assessed at 5% and 20% detection thresholds. Virological outcome was assessed using Cox regression in 837 of 920 ART initiators with at least 1 follow-up VL after ART initiation. Results PDR prevalence was 9.5% (109/1148) and 12.8% (147/1148) at 20% and 5% thresholds, respectively. After a median of 1.36 years (interquartile range, 0.91–2.13), mostly on fixed-dose combination tenofovir/emtricitabine/efavirenz, presence of both nonnucleoside reverse transcriptase inhibitor (NNRTI)/nucleoside reverse transcriptase inhibitor PDR vs no PDR was associated with longer time to VS (adjusted hazard ratio [aHR], 0.32; 95% confidence interval [CI], 0.12–0.86), while there was no difference between those with only NNRTI PDR vs no PDR (aHR, 1.05; 95% CI, 0.82–1.34) at the 5% threshold. Similar differences were observed for mutations detected at the 20% threshold, although without statistical significance. Conclusions NGS uncovered a high prevalence of PDR among participants enrolled in trial clinics in rural KwaZulu-Natal. Dual-class PDR to a mainly tenofovir/emtricitabine/efavirenz regimen was associated with poorer VS. However, there was no impact of NNRTI PDR alone. Clinical Trials Tegistration NCT01509508; South African National Clinical Trials Register: DOH-27-0512-3974." @default.
• W2896615022 created "2018-10-26" @default.
• W2896615022 creator A5017146733 @default.
• W2896615022 creator A5022528662 @default.
• W2896615022 creator A5026234029 @default.
• W2896615022 creator A5031518026 @default.
• W2896615022 creator A5049440373 @default.
• W2896615022 creator A5050061959 @default.
• W2896615022 creator A5051373841 @default.
• W2896615022 creator A5053100916 @default.
• W2896615022 creator A5071612716 @default.
• W2896615022 creator A5087956623 @default.
• W2896615022 date "2018-10-15" @default.
• W2896615022 modified "2023-10-17" @default.
• W2896615022 title "Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial" @default.
• W2896615022 cites W127451339 @default.
• W2896615022 cites W1692190376 @default.
• W2896615022 cites W1982799563 @default.
• W2896615022 cites W1988521171 @default.
• W2896615022 cites W2011224791 @default.
• W2896615022 cites W2036408211 @default.
• W2896615022 cites W2091460793 @default.
• W2896615022 cites W2094241860 @default.
• W2896615022 cites W2103414045 @default.
• W2896615022 cites W2104451608 @default.
• W2896615022 cites W2105064834 @default.
• W2896615022 cites W2105087430 @default.
• W2896615022 cites W2109046728 @default.
• W2896615022 cites W2109064013 @default.
• W2896615022 cites W2126014281 @default.
• W2896615022 cites W2128880918 @default.
• W2896615022 cites W2145441111 @default.
• W2896615022 cites W2252811454 @default.
• W2896615022 cites W2289938826 @default.
• W2896615022 cites W2315749602 @default.
• W2896615022 cites W2333158910 @default.
• W2896615022 cites W2508191793 @default.
• W2896615022 cites W2530015372 @default.
• W2896615022 cites W2557772666 @default.
• W2896615022 cites W2589883615 @default.
• W2896615022 cites W2773554166 @default.
• W2896615022 cites W2775758586 @default.
• W2896615022 cites W4230500325 @default.
• W2896615022 cites W4240755780 @default.
• W2896615022 doi "https://doi.org/10.1093/cid/ciy881" @default.
• W2896615022 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6603266" @default.
• W2896615022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30321314" @default.
• W2896615022 hasPublicationYear "2018" @default.
• W2896615022 type Work @default.
• W2896615022 sameAs 2896615022 @default.
• W2896615022 citedByCount "47" @default.
• W2896615022 countsByYear W28966150222018 @default.
• W2896615022 countsByYear W28966150222019 @default.
• W2896615022 countsByYear W28966150222020 @default.
• W2896615022 countsByYear W28966150222021 @default.
• W2896615022 countsByYear W28966150222022 @default.
• W2896615022 crossrefType "journal-article" @default.
• W2896615022 hasAuthorship W2896615022A5017146733 @default.
• W2896615022 hasAuthorship W2896615022A5022528662 @default.
• W2896615022 hasAuthorship W2896615022A5026234029 @default.
• W2896615022 hasAuthorship W2896615022A5031518026 @default.
• W2896615022 hasAuthorship W2896615022A5049440373 @default.
• W2896615022 hasAuthorship W2896615022A5050061959 @default.
• W2896615022 hasAuthorship W2896615022A5051373841 @default.
• W2896615022 hasAuthorship W2896615022A5053100916 @default.
• W2896615022 hasAuthorship W2896615022A5071612716 @default.
• W2896615022 hasAuthorship W2896615022A5087956623 @default.
• W2896615022 hasBestOaLocation W28966150221 @default.
• W2896615022 hasConcept C114851261 @default.
• W2896615022 hasConcept C119060515 @default.
• W2896615022 hasConcept C126322002 @default.
• W2896615022 hasConcept C142462285 @default.
• W2896615022 hasConcept C159047783 @default.
• W2896615022 hasConcept C207103383 @default.
• W2896615022 hasConcept C2777351918 @default.
• W2896615022 hasConcept C2779130552 @default.
• W2896615022 hasConcept C2779778239 @default.
• W2896615022 hasConcept C2781432083 @default.
• W2896615022 hasConcept C2993143319 @default.
• W2896615022 hasConcept C3013748606 @default.
• W2896615022 hasConcept C44249647 @default.
• W2896615022 hasConcept C71924100 @default.
• W2896615022 hasConcept C86803240 @default.
• W2896615022 hasConcept C89423630 @default.
• W2896615022 hasConceptScore W2896615022C114851261 @default.
• W2896615022 hasConceptScore W2896615022C119060515 @default.
• W2896615022 hasConceptScore W2896615022C126322002 @default.
• W2896615022 hasConceptScore W2896615022C142462285 @default.
• W2896615022 hasConceptScore W2896615022C159047783 @default.
• W2896615022 hasConceptScore W2896615022C207103383 @default.
• W2896615022 hasConceptScore W2896615022C2777351918 @default.
• W2896615022 hasConceptScore W2896615022C2779130552 @default.
• W2896615022 hasConceptScore W2896615022C2779778239 @default.
• W2896615022 hasConceptScore W2896615022C2781432083 @default.
• W2896615022 hasConceptScore W2896615022C2993143319 @default.
• W2896615022 hasConceptScore W2896615022C3013748606 @default.
• W2896615022 hasConceptScore W2896615022C44249647 @default.
• W2896615022 hasConceptScore W2896615022C71924100 @default.

• next